Back to Search
Start Over
Feasibility, Adherence and Efficacy of Liraglutide Treatment in a Sample of Individuals With Mood Disorders and Obesity
Feasibility, Adherence and Efficacy of Liraglutide Treatment in a Sample of Individuals With Mood Disorders and Obesity
- Source :
- Frontiers in Psychiatry, Frontiers in Psychiatry, Vol 9 (2019)
- Publication Year :
- 2019
-
Abstract
- Background Liraglutide is a once-daily injectable medication approved for the treatment of obesity. Hereby we report the feasibly, adherence and efficacy of liraglutide treatment in a sample of individuals with mood disorders and obesity. Methods and Sample Twenty-nine patients with Bipolar or Major Depressive Disorder received liraglutide once daily subcutaneously at a dose gradually titrated from 0.6 mg to 3 mg. All patients were obese and had previously failed multiple healthy lifestyle interventions, including exercise and diet programs. Patients’ weight was recorded before liraglutide treatment (T0) and then 1 (T1), 3 (T3), and 6 months (T6) following T0. Results Mean baseline (T0) weight was 110.54 Kg (± 24.95). Compared to baseline, the percentage of weight loss was 3.37 % at T1, 7.85% at T3 and 10.20% at T6. Thirty-one percent (n = 9) of patients had no side effects, 34.48% (n = 10) had one, 24.14% (n = 7) had two, and 10.34% (n=3) had three side effects. All 29 subjects were still on liraglutide at T1; 79.31% and 48.28% were on liraglutide at T3 and T6. No significant relationship was found between liraglutide dose and likelihood to continue the medication. No patient showed a worsening of the psychiatric condition due to liraglutide treatment. Acceptability and satisfaction with treatment were good for the 48% that completed the study. Conclusions Liraglutide treatment was efficacious, accepted and tolerated by approximately 50% of our sample, followed up for a period of 180 days. Larger, longer, controlled, prospective studies are warranted.
- Subjects :
- medicine.medical_specialty
obesity
lcsh:RC435-571
mood
03 medical and health sciences
0302 clinical medicine
depressive disorder
Weight loss
lcsh:Psychiatry
Internal medicine
Medicine
Prospective cohort study
Depression (differential diagnoses)
Psychiatry
liraglutide
business.industry
Liraglutide
bipolar
depression
Brief Research Report
medicine.disease
Obesity
030227 psychiatry
Psychiatry and Mental health
Mood
Mood disorders
Major depressive disorder
medicine.symptom
business
030217 neurology & neurosurgery
medicine.drug
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Frontiers in Psychiatry, Frontiers in Psychiatry, Vol 9 (2019)
- Accession number :
- edsair.doi.dedup.....c60e23c4366eb0269df0cb0fc034020b